Chester Mathis Selected Research

type 3 familial Alzheimer disease

1/2018

Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chester Mathis Research Topics

Disease

4	Cognitive Dysfunction 01/2019 - 05/2017
3	Dementia (Dementias) 01/2019 - 11/2014
3	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 04/2005
1	Atherosclerosis 01/2019
1	Coronary Disease (Coronary Heart Disease) 01/2019
1	Down Syndrome (Down's Syndrome) 01/2018
1	type 3 familial Alzheimer disease 01/2018
1	Amyloidosis 01/2018
1	Atrophy 11/2014
1	Mood Disorders (Mood Disorder) 10/2007

Drug/Important Bio-Agent (IBA)

4	Amyloid (Amyloid Fibrils)IBA 01/2018 - 11/2014
2	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2018 - 12/2014
2	Amyloid beta-PeptidesIBA 05/2017 - 04/2005
1	EquolIBA 01/2019
1	IsoflavonesIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	N- (2- (4- (2- methoxyphenyl)- 1- piperazinyl)ethyl)- N- (2- pyridinyl)cyclohexanecarboxamideIBA 10/2007